Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 88

1.

The parasitic wasp Cotesia congregata uses multiple mechanisms to control host (Manduca sexta) behaviour.

Adamo SA, Kovalko I, Turnbull KF, Easy RH, Miles CI.

J Exp Biol. 2016 Sep 15. pii: jeb.145300. [Epub ahead of print]

PMID:
27634401
2.

Risk factors for requiring intravenous antibiotic therapy in hospital and 30-day readmission for exacerbations of bronchiectasis.

Velu PP, Bedi P, Turnbull K, Hill AT.

QJM. 2016 Apr 13. pii: hcw057. [Epub ahead of print]

PMID:
27081209
3.

Reconfiguration of the immune system network during food limitation in the caterpillar Manduca sexta.

Adamo SA, Davies G, Easy R, Kovalko I, Turnbull KF.

J Exp Biol. 2016 Mar;219(Pt 5):706-18. doi: 10.1242/jeb.132936. Epub 2016 Jan 8.

4.

Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.

Brümmendorf TH, Cortes JE, Khoury HJ, Kantarjian HM, Kim DW, Schafhausen P, Conlan MG, Shapiro M, Turnbull K, Leip E, Gambacorti-Passerini C, Lipton JH.

Br J Haematol. 2016 Jan;172(1):97-110. doi: 10.1111/bjh.13801. Epub 2015 Nov 4.

5.

Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.

Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW; ABSORB III Investigators.

N Engl J Med. 2015 Nov 12;373(20):1905-15. doi: 10.1056/NEJMoa1509038. Epub 2015 Oct 12.

6.

Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.

Gambacorti-Passerini C, Kantarjian HM, Kim DW, Khoury HJ, Turkina AG, Brümmendorf TH, Matczak E, Bardy-Bouxin N, Shapiro M, Turnbull K, Leip E, Cortes JE.

Am J Hematol. 2015 Sep;90(9):755-68. doi: 10.1002/ajh.24034. Epub 2015 Jun 1.

7.

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators.

N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.

8.

Crystal structure of 4-(2-bromo-prop-ion-yl)-3-phenyl-sydnone.

Grossie D, Harrison L, Turnbull K.

Acta Crystallogr Sect E Struct Rep Online. 2014 Oct 18;70(Pt 11):o1165-6. doi: 10.1107/S1600536814022260. eCollection 2014 Nov 1.

9.

A prospective cohort study of the use of domiciliary intravenous antibiotics in bronchiectasis.

Bedi P, Sidhu MK, Donaldson LS, Chalmers JD, Smith MP, Turnbull K, Pentland JL, Scott J, Hill AT.

NPJ Prim Care Respir Med. 2014 Oct 23;24:14090. doi: 10.1038/npjpcrm.2014.90.

10.

Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study.

Isakoff SJ, Wang D, Campone M, Calles A, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Calvo E.

Br J Cancer. 2014 Nov 25;111(11):2058-66. doi: 10.1038/bjc.2014.508. Epub 2014 Oct 7.

11.

Prospective evaluation of unmet needs of rural and aboriginal cancer survivors in Northern British Columbia.

Olson RA, Howard F, Turnbull K, Munroe D, Zirul C, Manji R, Tobin P, Ward A.

Curr Oncol. 2014 Apr;21(2):e179-85. doi: 10.3747/co.21.1729.

12.

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.

Gambacorti-Passerini C, Brümmendorf TH, Kim DW, Turkina AG, Masszi T, Assouline S, Durrant S, Kantarjian HM, Khoury HJ, Zaritskey A, Shen ZX, Jin J, Vellenga E, Pasquini R, Mathews V, Cervantes F, Besson N, Turnbull K, Leip E, Kelly V, Cortes JE.

Am J Hematol. 2014 Jul;89(7):732-42. doi: 10.1002/ajh.23728. Epub 2014 Apr 28.

13.

Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I.

Oncologist. 2014 Apr;19(4):348-9. doi: 10.1634/theoncologist.2014-0021. Epub 2014 Mar 27.

14.

Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I.

Oncologist. 2014 Apr;19(4):346-7. doi: 10.1634/theoncologist.2014-0022. Epub 2014 Mar 27.

15.

Access to medical and supportive care for rural and remote cancer survivors in northern British Columbia.

Fuchsia Howard A, Smillie K, Turnbull K, Zirul C, Munroe D, Ward A, Tobin P, Kazanjian A, Olson R.

J Rural Health. 2014 Summer;30(3):311-21. doi: 10.1111/jrh.12064. Epub 2014 Feb 1.

PMID:
24483272
16.

4-Acetyl-3-[2-(eth-oxy-carbon-yl)phen-yl]sydnone.

Grossie D, Harrison L, Turnbull K.

Acta Crystallogr Sect E Struct Rep Online. 2013 Oct 19;69(Pt 11):o1662. doi: 10.1107/S1600536813027207. eCollection 2013 Oct 19.

17.

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.

Kantarjian HM, Cortes JE, Kim DW, Khoury HJ, Brümmendorf TH, Porkka K, Martinelli G, Durrant S, Leip E, Kelly V, Turnbull K, Besson N, Gambacorti-Passerini C.

Blood. 2014 Feb 27;123(9):1309-18. doi: 10.1182/blood-2013-07-513937. Epub 2013 Dec 17. Erratum in: Blood. 2014 Aug 7;124(6):981.

18.

Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.

Gandhi L, Bahleda R, Tolaney SM, Kwak EL, Cleary JM, Pandya SS, Hollebecque A, Abbas R, Ananthakrishnan R, Berkenblit A, Krygowski M, Liang Y, Turnbull KW, Shapiro GI, Soria JC.

J Clin Oncol. 2014 Jan 10;32(2):68-75. doi: 10.1200/JCO.2012.47.2787. Epub 2013 Dec 9.

19.

3-{5-Bromo-2-[(tri-phenyl-phosphanyl-idene)amino]-phen-yl}-4,5-di-hydro-1,2,3-oxa-diazol-3-ylium-5-olate.

Grossie D, Harrison L, Turnbull K.

Acta Crystallogr Sect E Struct Rep Online. 2013 Jul 3;69(Pt 8):o1196. doi: 10.1107/S1600536813017765. eCollection 2013.

20.
Items per page

Supplemental Content

Loading ...
Write to the Help Desk